Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.
Novel biologics for the treatment of pediatric severe asthma
Licari A.;Castagnoli R.;Tondina E.;Marseglia A.;Brambilla I.;Marseglia G. L.
2019-01-01
Abstract
Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
